Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

357 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R; Alzheimer’s Disease Neuroimaging Initiative. Liu-Seifert H, et al. Among authors: raskin j. J Alzheimers Dis. 2015;47(1):205-14. doi: 10.3233/JAD-142508. J Alzheimers Dis. 2015. PMID: 26402769 Free PMC article. Clinical Trial.
Drug development in Alzheimer's disease: the path to 2025.
Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Cummings J, et al. Among authors: raskin j. Alzheimers Res Ther. 2016 Sep 20;8:39. doi: 10.1186/s13195-016-0207-9. Alzheimers Res Ther. 2016. PMID: 27646601 Free PMC article. Review.
On the path to 2025: understanding the Alzheimer's disease continuum.
Aisen PS, Cummings J, Jack CR Jr, Morris JC, Sperling R, Frölich L, Jones RW, Dowsett SA, Matthews BR, Raskin J, Scheltens P, Dubois B. Aisen PS, et al. Among authors: raskin j. Alzheimers Res Ther. 2017 Aug 9;9(1):60. doi: 10.1186/s13195-017-0283-5. Alzheimers Res Ther. 2017. PMID: 28793924 Free PMC article. Review.
Representativeness of European clinical trial populations in mild Alzheimer's disease dementia: a comparison of 18-month outcomes with real-world data from the GERAS observational study.
Reed C, Belger M, Dell'Agnello G, Kahle-Wrobleski K, Sethuraman G, Hake A, Raskin J, Henley D. Reed C, et al. Among authors: raskin j. Alzheimers Res Ther. 2018 Apr 3;10(1):36. doi: 10.1186/s13195-018-0360-4. Alzheimers Res Ther. 2018. PMID: 29615123 Free PMC article. Clinical Trial.
Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia.
Willis BA, Sundell K, Lachno DR, Ferguson-Sells LR, Case MG, Holdridge K, DeMattos RB, Raskin J, Siemers ER, Dean RA. Willis BA, et al. Among authors: raskin j. Alzheimers Dement (N Y). 2018 Nov 9;4:652-660. doi: 10.1016/j.trci.2018.10.001. eCollection 2018. Alzheimers Dement (N Y). 2018. PMID: 30511011 Free PMC article.
357 results